|
|
|
Insider
Information: |
Mueller Peter |
Relationship: |
Director |
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
2 |
|
Direct
Shares |
311,837 |
|
Indirect Shares
|
25,571 |
|
|
Direct
Value |
$66,559,832 |
|
|
Indirect Value
|
$11,843,209 |
|
|
Total
Shares |
337,408 |
|
|
Total
Value |
$78,403,041 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Vertex Pharmaceuticals Inc |
VRTX |
EVP, Global R&D, CSO |
2014-06-16 |
143,517 |
2014-06-16 |
25,571 |
Premium* |
|
Bioxcel Therapeutics Inc |
BTAI |
Director |
2019-08-23 |
168,320 |
2018-12-04 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
141 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 4 of 6
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-11-15 |
4 |
OE |
$10.41 |
$16,656 |
D/D |
1,600 |
120,834 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2010-11-15 |
4 |
AS |
$34.43 |
$55,088 |
D/D |
(1,600) |
119,234 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-02-03 |
4 |
A |
$0.01 |
$145 |
D/D |
14,501 |
133,735 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-04-11 |
4 |
AS |
$47.83 |
$1,921,020 |
D/D |
(40,000) |
133,735 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-04-11 |
4 |
OE |
$10.41 |
$638,025 |
D/D |
40,000 |
173,735 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-04-15 |
4 |
OE |
$10.41 |
$26,025 |
D/D |
2,500 |
136,235 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-04-15 |
4 |
AS |
$47.28 |
$118,716 |
D/D |
(2,500) |
133,735 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-04-25 |
4 |
OE |
$16.32 |
$204,000 |
D/D |
12,500 |
146,235 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-04-25 |
4 |
AS |
$50.00 |
$625,000 |
D/D |
(12,500) |
133,735 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-05-16 |
4 |
OE |
$10.41 |
$26,025 |
D/D |
2,500 |
136,235 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-05-16 |
4 |
AS |
$55.44 |
$142,554 |
D/D |
(2,500) |
133,735 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-06-15 |
4 |
AS |
$46.50 |
$116,698 |
D/D |
(2,500) |
133,735 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-06-15 |
4 |
OE |
$10.41 |
$26,025 |
D/D |
2,500 |
136,235 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-07-15 |
4 |
OE |
$10.41 |
$26,025 |
D/D |
2,500 |
136,235 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-07-15 |
4 |
AS |
$50.68 |
$126,700 |
D/D |
(2,500) |
133,735 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-08-29 |
4 |
OE |
$10.41 |
$103,367 |
D/D |
9,500 |
143,235 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-08-29 |
4 |
AS |
$45.01 |
$427,595 |
D/D |
(9,500) |
133,735 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-09-15 |
4 |
OE |
$11.27 |
$107,065 |
D/D |
9,500 |
143,235 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-09-15 |
4 |
AS |
$50.03 |
$476,848 |
D/D |
(9,500) |
133,735 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-09-20 |
4 |
AS |
$52.50 |
$1,312,500 |
D/D |
(25,000) |
133,735 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2011-09-20 |
4 |
OE |
$17.16 |
$441,390 |
D/D |
25,000 |
158,735 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2012-02-02 |
4 |
A |
$0.01 |
$145 |
D/D |
14,501 |
148,236 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2012-05-07 |
4 |
AS |
$52.13 |
$4,216,085 |
D/D |
(79,500) |
148,236 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2012-05-07 |
4 |
OE |
$11.27 |
$1,346,025 |
D/D |
79,500 |
227,736 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global R&D, CSO |
|
2012-06-15 |
4 |
OE |
$16.32 |
$106,080 |
D/D |
6,500 |
138,816 |
0 |
- |
|
141 Records found
|
|
Page 4 of 6 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|